Thioaptamers targeting dengue virus type-2 envelope protein domain III.

ABSTRACT: Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM.

SUBMITTER: Gandham SH 

PROVIDER: S-EPMC4272640 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature